Lung Transplant Recipient
7
3
3
1
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
14.3%
1 terminated out of 7 trials
50.0%
-36.6% vs benchmark
29%
2 trials in Phase 3/4
100%
1 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (7)
BRIDGE - Blocking Receptor of IL-1β for Donor Graft Edema Reduction
Tubeless Strategy in Lung Transplantation: A Prospective Single-Arm Study
Combination Letermovir and Standard of Care Antiviral for Enhanced Antiviral Response in Cytomegalovirus Infection in Lung Transplant Recipients
Combined Light, ExVivo, and Antivirals for Recipients of Lungs From HBV Donors
High-Dose Moderna mRNA-1273 Booster Study for Lung Transplant Recipients
DSA Intragraft in Lung Transplantation: Diagnostic and Prognostic Value in Antibody Mediated Rejection
Safety and Efficacy Study of Inhaled AmBisome for Prevention of Aspergillus Colonization in Lung Transplant Recipients